Skip to main content
    1. See Our Science

    • Clinical Pipeline

    UCB is committed to developing novel treatments to address the unmet needs of patients living with severe diseases in immunology and neurology, including rare diseases. Our promising pipeline of antibody-based and small molecule agents are being rigorously evaluated in multiple ongoing clinical trials. These agents and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.

    Immunology Late-Stage Pipeline
    Immunology Late-Stage Pipeline
    Immunology Late-Stage Pipeline Mobile
    Neurology Late-Stage Pipeline
    Neurology Late-Stage Pipeline
    Neurology Late-Stage Pipeline Mobile

    The information provided here represents molecules that are currently under clinical investigation and/or investigational uses of approved products which are not approved by the U.S. Food and Drug Administration.

    For more information on UCB’s full pipeline of products under clinical development, visit UCB R&D pipeline.